Targeting breast cancer metastases using patient-derived models
Official title: Research Project 2 Proteogenomic-guided therapeutic targeting of breast cancer patient-derived xenograft metastases
Funded at Virginia Commonwealth University · NIH-10890853 · Data updated 2026-11-12
This study is looking at breast cancer in patients of Black ancestry to create models that help us understand how aggressive types of breast cancer behave and spread, and to see if certain drug combinations, like selinexor, can effectively treat it, all with the goal of improving treatment for everyone.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project start | July 19, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $254,405 |
| NIH project number | 5U54CA283762-02 |
| Project ID | NIH-10890853 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are breast cancer patients, especially those of Black ancestry, who have been diagnosed with Basal-like Triple-Negative Breast Cancer.
✕Less likely to help
Patients with non-metastatic breast cancer or those with other cancer types may not receive benefit from this research.
What this research studies
This research focuses on developing patient-derived xenograft (PDX) models from breast cancer patients, particularly those of Black ancestry, to better understand the genetic and proteomic profiles of aggressive breast cancer subtypes. The project aims to identify how these tumors spread to different organs and evaluate the effectiveness of specific drug combinations, including selinexor, in treating metastatic breast cancer. By utilizing these models, the research seeks to address disparities in breast cancer treatment and outcomes among different ancestral groups.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with aggressive forms of breast cancer.
How similar studies have gone: Other research has shown promise in using patient-derived models to study cancer, indicating that this approach could yield valuable insights and therapeutic strategies.
Where this research is happening
-
Virginia Commonwealth University
Richmond, United States Active
Researchers
- Principal investigator: Harrell, Joshua (Chuck) — Virginia Commonwealth University
- Study coordinator: Harrell, Joshua (Chuck)
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Gut bacteria and metabolites linked to breast density and cancer risk
A small, patient-friendly study will explore whether gut bacteria and their byproducts are connected to high breast density, which can raise cancer risk and make screening less accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.